摘要
目的 探究复方苦参注射液联合TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)化疗方案治疗HER-2阳性乳腺癌的疗效及安全性.方法 选取 2016 年 1 月至 2018 年 1 月新乡市第二人民医院收治的 102 例HER-2 阳性乳腺癌患者,采用随机数字表法分为对照组和研究组,各 51 例.对照组采用TCbHP化疗方案治疗,研究组采用复方苦参注射液联合TCbHP化疗方案治疗.比较两组临床疗效、治疗前及治疗 3 个周期后生存质量测定量表简表(QOL-BREF)评分,中医证候积分,血清肿瘤标志物[糖类抗原 153(CA153)、糖类抗原 125(CA125)、糖类抗原 199(CA199)、癌胚抗原(CEA)]水平,血清癌胚抗原相关细胞黏附分子 1(CEACAM1),四跨膜蛋白超家族成员 1(TM4SF1)水平,5 年生存率.结果 研究组客观缓解率(ORR)(62.75%)高于对照组(43.14%)(P<0.05).治疗 3 个周期后,研究组QOL-BREF评分高于对照组(P<0.05);研究组中医证候积分均低于对照组(P<0.05);研究组血清CA153、CA125、CA199、CEA水平低于对照组(P<0.05);研究组血清CEACAM1、TM4SF1 水平低于对照组(P<0.05).治疗期间研究组血小板降低、白细胞降低、肝功能损害、腹泻发生率(13.73%、7.84%、3.92%、5.88%)低于对照组(31.37%、23.53%、17.65%、21.57%)(P<0.05).研究组 5 年生存率(44.68%)高于对照组(24.49%)(P<0.05).结论 采用复方苦参注射液联合TCbHP化疗方案治疗可显著抑制HER-2 阳性乳腺癌患者病情进展,缓解症状,延长生存期,提高临床疗效及生存质量.
Abstract
Objective To explore the efficacy and safety of compound sophora flavescens injection combined with TCbHP(docetaxel+carboplatin+trastuzumab+patuzumab)chemotherapy in the treatment of HER-2 positive breast cancer.Methods A total of 102 HER-2 positive breast cancer patients admitted to Second People's Hospital of Xinxiang City from January 2016 to January 2018 were selected and randomly divided into the control group and the study group,with 51 cases in each group.The control group was treated with TCbHP chemotherapy,and the study group was treated with compound matrine injection assisted with TCbHP chemotherapy.Compare the clinical efficacy of the two groups,as well as the QOL-BREF scores,serum tumor markers[carbohydrate antigen 153(CA153),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)]levels,serum carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1),and member of the four-transmembrane protein superfamily 1(TM4SF1)levels before and after 3 cycles of treatment,and compare the 5-year survival rates of the two groups.Results The objective remission rate(ORR)of the study group(62.75%)was higher than that of the control group(43.14%)(P<0.05).After 3 cycles of treatment,the QOL-BREF score of the study group was higher than that of the control group(P<0.05);the levels of serum CA153,CA125,CA199 and CEA in the study group were lower than those in the control group(P<0.05);the serum levels of CEACAM1 and TM4SF1 in the study group were lower than those in the control group(P<0.05).During the treatment period,the incidence of thrombocytopenia,leukopenia,liver function damage,and diarrhea in the study group(13.73%,7.84%,3.92%,5.88%)were lower than those in the control group(31.37%,23.53%,17.65%,21.57%)(P<0.05).The 5-year survival rate of the study group(44.68%)was higher than that of the control group(24.49%)(P<0.05).Conclusion Compound sophora flavescens injection combined with TCbHP chemotherapy can significantly inhibit the progression of HER-2 positive breast cancer patients,prolong the survival period,and improve clinical efficacy and quality of life.
维普
万方数据